On a win­ning streak, Heron rock­ets up 30% on PhI­Ib pain drug da­ta

More than dou­bling its stock since the first of the year, San Diego’s Heron Ther­a­peu­tics re­port­ed yet an­oth­er slam dunk Thurs­day morn­ing with news that its pain drug de­liv­ered in two more in­di­ca­tions. That’s af­ter the com­pa­ny re­port­ed stel­lar Phase III da­ta just three months ago, and a FDA OK on a dif­fer­ent drug be­fore that.

Heron’s in­vestors are pleased with the news, with the com­pa­ny’s stock $HRTX jump­ing 30% in pre-mar­ket trad­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.